BC Week In Review | Mar 30, 2018
Clinical News

MiMedx's AmnioFix Injectable meets in Phase IIb for plantar fasciitis

MiMedx Group Inc. (NASDAQ:MDXG) reported top-line data from the single-blind, U.S. Phase IIb IND trial in 145 patients with plantar fasciitis showing that a single 40 mg dose of AmnioFix Injectable met the primary endpoint...
Items per page:
1 - 1 of 1